NEOGENOMICS INC (NEO) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NEO currently has 129M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 2.4% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 28, 2026 |
10-Q filing | 129.2M shares outstanding |
130M | 0 |
| Oct 28, 2025 |
10-Q filing | 128.4M shares outstanding |
130M | 0 |
| Apr 29, 2025 |
10-Q filing | 127.4M shares outstanding |
130M | 0 |
| Feb 18, 2025 |
10-K filing | 126.7M shares outstanding |
130M | 0 |
| Nov 05, 2024 |
10-Q filing | 127.0M shares outstanding |
130M | 0 |
| Jul 30, 2024 |
10-Q filing | 126.4M shares outstanding |
130M | 0 |
| Apr 30, 2024 |
10-Q filing | 126.1M shares outstanding |
130M | 0 |
| Feb 20, 2024 |
10-K filing | 125.5M shares outstanding |
130M | 0 |
| Nov 06, 2023 |
10-Q filing | 125.7M shares outstanding |
130M | 0 |
| Aug 08, 2023 |
10-Q filing | 125.4M shares outstanding |
130M | 0 |
| May 09, 2023 |
10-Q filing | 125.0M shares outstanding |
130M | 0 |
| Feb 24, 2023 |
10-K filing | 124.2M shares outstanding |
120M | 0 |
| Nov 08, 2022 |
10-Q filing | 124.4M shares outstanding |
120M | 0 |
| Aug 09, 2022 |
10-Q filing | 124.1M shares outstanding |
120M | 0 |
| May 09, 2022 |
10-Q filing | 123.6M shares outstanding |
120M | 0 |
| Feb 25, 2022 |
10-K filing | 120.0M shares outstanding |
120M | 0 |
| Nov 04, 2021 |
10-Q filing | 122.6M shares outstanding |
120M | 0 |
| Aug 09, 2021 |
10-Q filing | 118.3M shares outstanding |
120M | 0 |
| May 06, 2021 |
10-Q filing | 116.2M shares outstanding |
120M | 0 |
| Feb 25, 2021 |
10-K filing | 111.8M shares outstanding |
110M | 0 |
| Jan 11, 2021 |
8-K filing: NeoGenomics, Inc. announced the pricing of its underwritten public offering of 4.1 million shares of its Common Stock at a public offering price of $49.00 per share and an underwritten public offering of $300 million aggregate principal amount of 0.25% Convertible Senior Notes due 2028. |
110M | 0 |
| Oct 29, 2020 |
10-Q filing | 110.5M shares outstanding |
110M | 0 |
| Jul 31, 2020 |
10-Q filing | 107.9M shares outstanding |
110M | 0 |
| May 04, 2020 |
8-K filing: NeoGenomics, Inc. announced the pricing of its underwritten public offering of 4,400,000 shares of its common stock at a public offering price of $28.50 per share and an underwritten public offering of $175 million aggregate principal amount of 1.25% Convertible Senior Notes due 2025. |
100M | 0 |
| Apr 29, 2020 |
10-Q filing | 104.5M shares outstanding |
100M | 0 |
| Feb 28, 2020 |
10-K filing | 103.6M shares outstanding |
100M | 0 |